Tempus Bets on AI and Vast Health Data to Transform Cancer Care
November 16, 2026
Tempus was founded around 2015, after Eric Lefkofsky’s wife was diagnosed with breast cancer and he saw how little technology was being used in cancer care; he expected cheaper, more widespread sequencing to produce data clinicians would need better software to interpret.
To tackle that challenge, Tempus has built more than 8,000 two-way connections to hospital records across well over half of the United States, combining clinical information with molecular sequencing data; Lefkofsky says cleaning and structuring that information has required a long-term effort involving 600 to 700 engineers and product staff.
Lefkofsky says general-purpose AI cannot reliably interpret genomic data or specialized ECG readings without adaptation, so Tempus retrains models and validates them clinically and analytically to ensure recommendations are dependable and their reasoning understandable to physicians.
Lefkofsky sees healthcare as an approximately $6 trillion industry that has received relatively little AI investment, but says regulation and the complexity of care will slow adoption compared with consumer technology; he estimates three to five years for physician tools and seven to ten years for drug-development applications.
Demand from pharmaceutical and biotech companies is already translating into business: Lefkofsky says Tempus signed three deals worth at least $100 million in 2026, with Merck, Bristol Myers Squibb and an unnamed biotech.
Tempus reported about 23% revenue growth for the September 2026 quarter, with cancer-testing units up 32% and data and AI applications up 33%; its dataset reached 600 petabytes after expanding by 50 petabytes during the quarter.
Tempus is also moving into minimal residual disease detection through its planned acquisition of Personalis, which Lefkofsky says could help its blood tests detect cancer recurrence six to twelve months before a typical scan and let clinicians adjust treatment sooner.
Lefkofsky describes Personalis as a leading competitor in solid-tumor recurrence testing, and says the deal would extend Tempus’ stated cancer-care coverage from assessing risk and supporting treatment to monitoring for recurrence.
Summary based on 1 source
Get a daily email with more AI stories
Source

BigGo Finance • Nov 15, 2026
Blood Tests Will Catch Returning Cancer 12 Months Early | Tempus|MTS — BigGo Finance